Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis
CovidSurg-Can
1 other identifier
observational
1,000
1 country
1
Brief Summary
CovidSurg-Cancer is an international, multicentre, observational cohort study designed to evaluate the 30-day COVID-19 infection rates in elective cancer surgery during the COVID-19 pandemic. Centres can elect to include one or more cancer types in the study, in any combination, depending on local expertise and capacity. During the pilot study, investigators should enrol patients with confirmed diagnoses of:
- Colorectal cancer
- Oesophagogastric cancer As a rapid response study to the COVID-19 pandemic, included cancer types will evolve throughout the course of the CovidSurg-Cancer study period, for example, to include breast, liver, pancreatic, gynaecological, urological cancers, or sarcomas.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 30, 2020
CompletedFirst Submitted
Initial submission to the registry
May 11, 2020
CompletedFirst Posted
Study publicly available on registry
May 12, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedMay 12, 2020
May 1, 2020
9 months
May 11, 2020
May 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
30-day postoperative COVID-19 infection rate
Frequency of COVID-19 infection within 30 days
30 days
Secondary Outcomes (4)
30-day postoperative mortality rate
30-days
Postoperative critical care utilisation rate in high-risk cancer surgery patients.
30-days
Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery
More than 4 weeks from decision date
Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery
Up to 3-months
Study Arms (2)
Cohort 1
Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery completed during the COVID-19 pandemic
Cohort 2
Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery delayed or cancelled during the COVID-19 pandemic
Interventions
Eligibility Criteria
* Patients planned for curative cancer surgery that have surgery completed during the COVID-19 pandemic * Patients planned for curative cancer surgery that have surgery delayed or cancelled during the COVID-19 pandemic
You may qualify if:
- \- Any centre performing elective cancer surgery
- Adults (age ≥18 years) with a confirmed diagnosis of an included cancer type
- Decision made for surgical management with a curative intent
You may not qualify if:
- Surgery planned with non-curative intent
- Planned neoadjuvant therapy without a firm date for surgery, or awaiting restaging
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital del Henares
Madrid, Spain
Related Publications (3)
NIHR Global Health Research Unit on Global Surgery; STARSurg Collaborative. A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts. Lancet Digit Health. 2024 Jul;6(7):e507-e519. doi: 10.1016/S2589-7500(24)00065-7.
PMID: 38906616DERIVEDCOVIDSurg Collaborative. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study. Lancet Oncol. 2021 Nov;22(11):1507-1517. doi: 10.1016/S1470-2045(21)00493-9. Epub 2021 Oct 5.
PMID: 34624250DERIVEDGlasbey JC, Nepogodiev D, Simoes JFF, Omar O, Li E, Venn ML, Pgdme, Abou Chaar MK, Capizzi V, Chaudhry D, Desai A, Edwards JG, Evans JP, Fiore M, Videria JF, Ford SJ, Ganly I, Griffiths EA, Gujjuri RR, Kolias AG, Kaafarani HMA, Minaya-Bravo A, McKay SC, Mohan HM, Roberts KJ, San Miguel-Mendez C, Pockney P, Shaw R, Smart NJ, Stewart GD, Sundar Mrcog S, Vidya R, Bhangu AA; COVIDSurg Collaborative. Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. J Clin Oncol. 2021 Jan 1;39(1):66-78. doi: 10.1200/JCO.20.01933. Epub 2020 Oct 6.
PMID: 33021869DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Aneel Bhangu
University of Birmingham
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2020
First Posted
May 12, 2020
Study Start
March 30, 2020
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
May 12, 2020
Record last verified: 2020-05
Data Sharing
- IPD Sharing
- Will not share
No individual participant data will be made available to other researchers